Home › Companies › ALDEYRA THERAPEUTICS INC. › 2023-2024
Compiled from SEC Form N-PX filings and ALDEYRA THERAPEUTICS INC.’s Form 8-K, filed 2024-06-07 (Item 5.07 on EDGAR). Page generated 04 October 2026.
Explore ALDEYRA THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are ALDEYRA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-07 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Nancy B. Miller-Rich | 21,883,289 | -- | -- | 12,598,676 | 10,177,898 | Majority: yes |
| Elect Director: Ben R. Bronstein, M.D. | 22,697,358 | -- | -- | 11,784,607 | 10,177,898 | Majority: yes |
| Proposal 2: Ratification of Appointment of BDO USA, P.C | 44,100,430 | 372,785 | 186,648 | -- | -- | Majority: yes |
| Proposal 3: Advisory Vote on Executive Compensation | 31,493,319 | 2,862,040 | 126,606 | -- | 10,177,898 | Majority: yes |
Source: ALDEYRA THERAPEUTICS INC., Form 8-K, filed with the SEC on 2024-06-07 — read the filing on EDGAR.
Each item below shows how the 130 asset managers that disclosed a ALDEYRA THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 9 wordings of this item as funds reported it.
92% Majority: yes · of votes cast
ALDEYRA THERAPEUTICS INC.’s own tally for this item (“Proposal 3: Advisory Vote on Executive Compensation”): 31,493,319 for, 2,862,040 against, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 59,414,489 outstanding shares: 53.0% for, 5% against (58% of the company cast a for/against vote).
The 127 asset managers below cast 91% of the shares they voted on this item FOR (23,931,790 for, 2,403,820 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 9,221,412 | 0 | 0 | 0 | For |
| Vanguard | 3,875,203 | 0 | 0 | 0 | For |
| BlackRock | 3,087,109 | 0 | 0 | 0 | For |
| KENNEDY CAPITAL MANAGEMENT LLC | 1,232,089 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,028,231 | 0 | 0 | 0 | For |
| Fidelity | 963,820 | 0 | 0 | 0 | For |
| EAGLE ASSET MANAGEMENT INC | 876,705 | 0 | 0 | 0 | For |
| State Street | 866,959 | 0 | 0 | 0 | For |
| SEI | 0 | 739,083 | 0 | 0 | Against |
| Dimensional | 0 | 648,419 | 0 | 0 | Against |
| Northern Trust | 361,619 | 28 | 0 | 0 | For |
| PNC BANK, NATIONAL ASSOCIATION | 0 | 301,505 | 0 | 0 | Against |
| CARILLON SERIES TRUST | 283,577 | 0 | 0 | 0 | For |
| Charles Schwab | 251,050 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 0 | 225,990 | 0 | 0 | Against |
| Palo Alto Investors LP | 225,465 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 178,919 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 178,170 | 0 | 0 | 0 | For |
| WOODSTOCK CORP | 0 | 170,715 | 0 | 0 | Against |
| Equitable | 141,877 | 0 | 0 | 0 | For |
| Nuveen | 99,687 | 0 | 0 | 0 | For |
| TIAA | 98,308 | 0 | 0 | 0 | For |
| STRS OHIO | 82,300 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 78,150 | 0 | 0 | 0 | For |
| T. Rowe Price | 58,840 | 0 | 0 | 0 | For |
Showing the 25 largest of 127 asset managers. See all 127 in the interactive database.
Combines 3 wordings of this item as funds reported it.
66% Majority: yes · of votes cast
ALDEYRA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Ben R. Bronstein, M.D.”): 22,697,358 for, 11,784,607 withheld, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 59,414,489 outstanding shares: 38% for, 20% withheld (58% of the company cast a for/withheld vote).
The 41 asset managers below cast 100% of the shares they voted on this item FOR (2,907,026 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 0 | 0 | 3,783,308 | 0 | Abstain |
| BlackRock | 1,740,689 | 0 | 0 | 0 | For |
| Fidelity | 961,375 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 546,755 | 0 | Abstain |
| SEI | 0 | 0 | 369,002 | 0 | Abstain |
| CARILLON SERIES TRUST | 0 | 0 | 283,577 | 0 | Abstain |
| Equitable | 85,187 | 0 | 56,690 | 0 | For |
| Charles Schwab | 0 | 0 | 125,525 | 0 | Abstain |
| TIAA | 0 | 0 | 98,308 | 0 | Abstain |
| QUANTITATIVE MASTER SERIES LLC | 78,150 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 0 | 48,794 | 0 | Abstain |
| Managed Portfolio Series | 0 | 0 | 27,962 | 0 | Abstain |
| AIG/SunAmerica | 0 | 0 | 22,952 | 0 | Abstain |
| Jackson National | 0 | 0 | 21,117 | 0 | Abstain |
| Nationwide | 5,467 | 0 | 14,655 | 0 | Abstain |
| John Hancock | 0 | 0 | 18,921 | 0 | Abstain |
| Northern Trust | 0 | 0 | 17,712 | 0 | Abstain |
| American Century | 0 | 0 | 17,136 | 0 | Abstain |
| State Street | 0 | 0 | 16,858 | 0 | Abstain |
| Voya | 0 | 0 | 16,086 | 0 | Abstain |
| Brighthouse | 0 | 0 | 15,823 | 0 | Abstain |
| Pacific Life | 14,881 | 0 | 0 | 0 | For |
| Invesco | 0 | 0 | 11,271 | 0 | Abstain |
| Goldman Sachs | 10,813 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 10,567 | 0 | Abstain |
Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.
Combines 3 wordings of this item as funds reported it.
63% Majority: yes · of votes cast
ALDEYRA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Nancy B. Miller-Rich”): 21,883,289 for, 12,598,676 withheld, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 59,414,489 outstanding shares: 37% for, 21% withheld (58% of the company cast a for/withheld vote).
The 41 asset managers below cast 100% of the shares they voted on this item FOR (1,958,611 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 0 | 0 | 3,783,308 | 0 | Abstain |
| BlackRock | 1,740,689 | 0 | 0 | 0 | For |
| Fidelity | 0 | 0 | 961,375 | 0 | Abstain |
| Dimensional | 0 | 0 | 546,755 | 0 | Abstain |
| SEI | 0 | 0 | 369,002 | 0 | Abstain |
| CARILLON SERIES TRUST | 0 | 0 | 283,577 | 0 | Abstain |
| Equitable | 85,187 | 0 | 56,690 | 0 | For |
| Charles Schwab | 0 | 0 | 125,525 | 0 | Abstain |
| TIAA | 0 | 0 | 98,308 | 0 | Abstain |
| QUANTITATIVE MASTER SERIES LLC | 78,150 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 0 | 48,794 | 0 | Abstain |
| Managed Portfolio Series | 0 | 0 | 27,962 | 0 | Abstain |
| AIG/SunAmerica | 0 | 0 | 22,952 | 0 | Abstain |
| Jackson National | 0 | 0 | 21,117 | 0 | Abstain |
| Nationwide | 0 | 0 | 20,122 | 0 | Abstain |
| John Hancock | 0 | 0 | 18,921 | 0 | Abstain |
| Northern Trust | 17,712 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 17,136 | 0 | Abstain |
| State Street | 0 | 0 | 16,858 | 0 | Abstain |
| Voya | 0 | 0 | 16,086 | 0 | Abstain |
| Brighthouse | 0 | 0 | 15,823 | 0 | Abstain |
| Pacific Life | 14,881 | 0 | 0 | 0 | For |
| Invesco | 11,271 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 0 | 10,813 | 0 | Abstain |
| T. Rowe Price | 0 | 0 | 10,567 | 0 | Abstain |
Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.1% Majority: yes · of votes cast
ALDEYRA THERAPEUTICS INC.’s own tally for this item (“Proposal 2: Ratification of Appointment of BDO USA, P.C”): 44,100,430 for, 372,785 against, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 59,414,489 outstanding shares: 74% for, 0.7% against (75% of the company cast a for/against vote).
The 41 asset managers below cast 100% of the shares they voted on this item FOR (8,485,401 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,783,308 | 0 | 0 | 0 | For |
| BlackRock | 1,740,689 | 0 | 0 | 0 | For |
| Fidelity | 961,375 | 0 | 0 | 0 | For |
| Dimensional | 546,755 | 0 | 0 | 0 | For |
| SEI | 369,002 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 283,577 | 0 | 0 | 0 | For |
| Equitable | 141,877 | 0 | 0 | 0 | For |
| Charles Schwab | 125,525 | 0 | 0 | 0 | For |
| TIAA | 98,308 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 78,150 | 0 | 0 | 0 | For |
| Lincoln Financial | 48,794 | 0 | 0 | 0 | For |
| Managed Portfolio Series | 27,962 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 22,952 | 0 | 0 | 0 | For |
| Jackson National | 21,117 | 0 | 0 | 0 | For |
| Nationwide | 20,122 | 0 | 0 | 0 | For |
| John Hancock | 18,921 | 0 | 0 | 0 | For |
| Northern Trust | 17,712 | 0 | 0 | 0 | For |
| American Century | 17,136 | 0 | 0 | 0 | For |
| State Street | 16,858 | 0 | 0 | 0 | For |
| Voya | 16,086 | 0 | 0 | 0 | For |
| Brighthouse | 15,823 | 0 | 0 | 0 | For |
| Pacific Life | 14,881 | 0 | 0 | 0 | For |
| Invesco | 11,271 | 0 | 0 | 0 | For |
| Goldman Sachs | 10,813 | 0 | 0 | 0 | For |
| T. Rowe Price | 10,567 | 0 | 0 | 0 | For |
Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.
Ranked by the number of ALDEYRA THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 59,414,489 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | PERCEPTIVE ADVISORS LLC | 15.52% |
| 2 | Vanguard | 6.52% |
| 3 | BlackRock | 5.20% |
| 4 | KENNEDY CAPITAL MANAGEMENT LLC | 2.07% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 1.73% |
| 6 | Fidelity | 1.62% |
| 7 | EAGLE ASSET MANAGEMENT INC | 1.48% |
| 8 | State Street | 1.46% |
| 9 | SEI | 1.24% |
| 10 | Dimensional | 1.09% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| Perceptive Advisors LLC | 14.46% | DEF14A |
| BlackRock | 6.40% | 13F |
| Knoll Capital Management, LLC | 6.05% | DEF14A |
| Vanguard Group | 6.05% | 13F |
| Todd C. Brady, M.D., Ph.D. | 5.10% | DEF14A |
| Morgan Stanley | 1.82% | 13F |
| State Street | 1.58% | 13F |
| Dimensional Fund Advisors | 1.48% | 13F |
| Renaissance Technologies | 1.22% | 13F |
| Stephen G. Machatha, Ph.D. | 1.21% | DEF14A |
Percentages above are of 59,414,489 shares outstanding, as reported by ALDEYRA THERAPEUTICS INC. on its Form 10-Q dated 2024-04-30 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ALDEYRA THERAPEUTICS INC.’s 10-Q dated 2024-04-30. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.
At ALDEYRA THERAPEUTICS INC.'s shareholder meeting held 2024-06-04, in the 2023-2024 proxy season, 130 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 585 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF ALDEYRA THERAPEUTICS, INC.'S… — FOR was 92% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ALDEYRA THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-07.
ALDEYRA THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.